Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development.

Cancer metastasis reviews - 27 Mar 2026

Van Galen Joseph, Willis Stephen D, Bains Ashish, Small Sara H

Abstract excerpt

Acute myeloid leukemia (AML) is a lethal and rapidly progressive hematologic malignancy with high rates of relapse and treatment refractoriness. Management of AML is complicated by biological heterogeneity in a disease that is broadly defined by the clonal expansion of myeloblasts that otherwise play an important role in healthy marrow tissues. While subtypes of AML are increasingly defined by druggable driver...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to FLT3 gene
Share to IDH1 gene
Share to IDH2 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to NPM1 gene

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Neoplasm, Residual

Share to Nucleophosmin

Source

Open in PubMed Open full text

Identifiers

PMID: 41894068
DOI: 10.1007/s10555-026-10322-5
PMCID: PMC13031212

Genes

FLT3
IDH1
IDH2
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Measurable residual disease testing in acute myeloid leukemia: current state, foundational models, and tools for future development.PMID 41894068Read ↗

Minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid LeukemiaSemantic proximity Read ↗

Single cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemiaSemantic proximity Read ↗

Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaSemantic proximity Read ↗

Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia.Semantic proximity Read ↗

Novel Tools for Diagnosis and Monitoring of AML.Semantic proximity Read ↗

Next‐generation sequencing for measurable residual disease detection in acute myeloid leukaemiaSemantic proximity Read ↗

Prognostic and Therapeutic Implications of Measurable Residual Disease Detection Across Hematologic Malignancies: Clinical Impact on Relapse Prediction and Survival OutcomesSemantic proximity Read ↗

Diagnostic work‐up of acute myeloid leukemiaSemantic proximity Read ↗

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?Semantic proximity Read ↗

Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual DiseaseSemantic proximity Read ↗

Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.